Clotting in Medical Technology

Isis and Collaborators Present New Research at the ATVB Annual Conference

... has the potential to create a drug to decrease clotting without increasing bleeding. Both of these ... rapidly and efficiently evaluating individual clotting factors produced in the liver, we selected Factor ... we will have drugs that inhibit other individual clotting factors that demonstrate potential therapeutic ...

New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery

... from 84 postmenopausal women was tested for clotting activity before and after administration of oral ... a period of eight weeks. Women with borderline clotting issues showed "a significant acceleration" of clotting after oral estrogen therapy, but no significant ...

Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home

... Self-Testing, enable patients to test their clotting time at home in about a minute, using a small ... supplies before being able to monitor their own clotting time at home. Patient self-testing is also ... Patients who self-test notify their doctors of clotting time results so they can make the proper ...

ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)

... end of 2009. Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical ... medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, ...

Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia

... treated by replacement therapy, receiving purified versions of the clotting factor in which they are deficient. However, a significant number of ... treated with factor VIIa, a protease enzyme that can both initiate blood clotting and, at high doses, "bypass" the factor VIII-dependent step in ....

ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI

... expect to determine whether bivalirudin, a direct inhibitor of the clotting protein thrombin, is better than unfractionated heparin, an indirect ... preloading with a 600-mg dose of clopidogrel, a medication that prevents clotting by inhibiting platelets. "The distinguishing feature of our study is ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... About Edoxaban Edoxaban, the molecule originally referred to as DU-176b, is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing edoxaban as a potential new treatment for the prevention of both arterial and venous ...

CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency

... of fibrinogen, also called Factor I (one), limit the body's ability to form a clot. Certain fibrinogen levels usually indicate normal blood clotting ability. To determine fibrinogen levels and confirm a diagnosis, blood coagulation testing is needed. RiaSTAP is a purified fibrinogen ...

For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold

... needle returns the cleansed blood. Interventional radiologists monitor AV fistulas to avoid complications such as infection, blockage from clotting and poor blood flow. Interventional radiologists also keep AV fistulas or other accesses open or unclogged through minimally invasive techniques such ...

Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B

... About Hemophilia Hemophilia is a lifelong, inherited bleeding disorder caused by low levels or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... (ID-TLR) as compared to TAXUS (4.3 percent for XIENCE V vs. 6.9 percent for TAXUS, p-value=0.07)*. -- Low rates of stent thrombosis (blood clotting within the treated area) per the Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (1.3 percent for XIENCE V vs. ...

ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell

... to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field. Fibrocaps, the ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... ASH launched Blood: The Vital C o nnection (www.blood t hevitalconnection.org ) , a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood disorders including risk factors, preventive ...

Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes

... ASH launched Blood: The Vital C o nnection (www.blood t hevitalconnection.org) , a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood conditions including risk factors, preventive ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... ASH launched Blood: The Vital C o nnection (www.blood t hevitalconnection.or g ) , a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these blood conditions including risk factors, preventative ...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

... In September, ASH launched Blood: The Vital Connection ( www.bloodthevitalconnection.org ), a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood conditions including risk factors, preventive ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... ASH launched Blo o d: The Vital C o nnection (www.blood t hevitalconnection.org) , a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood conditions including risk factors, preventive ...

FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

... trademarks of Bayer. (C)Bayer HealthCare LLC KN-28-000-208 (1) MASAC Recommendation 179 Concerning Prophylaxis (Regular Administration of clotting Factor Concentrate to Prevent Bleeding) "MASAC recommends that prophylaxis be considered optimal therapy for individuals with severe hemophilia A and ...

Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use

... Antiplatelet agents (usually aspirin plus clopidogrel) are also recommended for patients after receiving coronary artery stents to prevent dangerous clotting that could cause a heart attack. As more Americans survive and live with heart disease in addition to conditions that require them to take NSAIDs ...

American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant

... complications such as postoperative bleeding and blood clots blocking a blood vessel occurred infrequently, but there was a high incidence of blood clotting in the pumps. Small heart pump devices have been available in Europe for many years, but they are not approved for use in North America. However, ...

Swedish in Seattle to Study Connections Between Preeclampsia and Migraine

... look at specific bio-markers in the blood." Platelets, a key element of blood clotting, are only activated when needed. For unclear reasons, higher clotting levels have been reported in migraine sufferers and women with preeclampsia. "That suggests a connection, but we need to test that hypothesis ...

KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research

... given as an injection to soldiers before going into battle. Phillips research is focusing on a molecule that "switches on" a gene to produce a blood clotting protein, Factor VII. When a blood vessel is broken, the bleeding reduces oxygen. Low oxygen would activate the Hemostat causing Factor VII to be ...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

... infusion doses of NU172 for four hours. In all four cohorts, NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time (ACT), prothrombin time (PT) and activated partial thromboplastin time (aPTT). The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in ...

First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan

... potential to overcome some of the issues that have been seen with other devices, including hemolysis caused by shear stress on red blood cells, and clotting risk caused by blood that does not circulate rapidly enough from all areas of the chamber," Pagani explains. "It also remains to be seen if this ...

Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women

... a variety of options for care in special patient groups." Antithrombotic and thrombolytic therapies are used to prevent and treat thrombosis or blood clotting that arises in arteries, veins, and the heart. Pregnant Women The new ACCP guidelines address challenging issues facing women who are pregnant or ...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

... from the single-center, Phase 1 trial showed that bolus doses of NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time (ACT). Upon discontinuation of NU172 the ACT showed a rapid return toward baseline with a plasma half-life of approximately 10 minutes. No ...

AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication

... as a result of peptic ulcer disease. PUB occurs when the ulcer erodes into an underlying blood vessel. The resulting blood loss can be significant as clotting can be impaired in the acidic environment. If after treatment, a peptic ulcer re-bleeds, there is an increased risk of morbidity and mortality(8) ...

First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System

... plaque and avoided placing the end of a shorter stent in the fatty plaque. Termination of a stent in a fatty plaque has been associated with clotting of the stent years after placement. "If doctors can identify these fatty plaques, we can recommend better treatment options to patients," says ...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

... involving more than 1,700 patients. Viprinex has been shown to rapidly reduce blood levels of fibrinogen, an important agent involved in blood clotting and blood viscosity. Elevated fibrinogen levels are a risk factor for stroke and may be associated with greater stroke disability. Prior studies with ...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

... bolus doses of NU172 in normal, healthy volunteers. In the trial, NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time (ACT). The 2.00 mg/kg bolus dose of NU172 achieved target ACTs of approximately 400 seconds. Upon withdrawal of NU172 the ACT showed a rapid ...

SPIRIT II Explores Long-Term Performance of XIENCE V Stent

... and the rates of cardiac death were 0.5 percent and 1.4 percent, respectively, a 64 percent reduction. There was no difference in the rates of blood clotting inside the stent, or stent thrombosis, at two years. In the 117 patients who had follow-up angiography at two years, there was no significant ...

Large Study Gives Nod to Drug-Eluting Stents in Heart Attack

... heart attack patients are already prone to forming blood clots in the coronary arteries, they might be at high risk for stent thrombosis, or sudden clotting inside the stent, particularly a drug-eluting stent. To evaluate the long-term safety and effectiveness of drug-eluting stents, Dr. Mauri and her ...

Drug-Eluting Stents Outperform Bare Stents in Heart Attack

... clinical practice. As for tirofiban and abciximab, both are in a class of medications known as glycoprotein 2b/3a inhibitors and prevent blood clotting by blocking hyperactivation of platelets. Tirofiban is an attractive alternative for several reasons: It is shorter-acting and is cleared from the ...

TRITON-TIMI 38 Stent Analysis Favors Prasugrel

... 75 mg daily for one year, or to a loading dose of 60 mg of prasugrel, followed by 10 mg daily for one year. Both medications prevent unwanted blood clotting by inhibiting the ability of platelets to clump together. Stephen D. Wiviott, MD, Brigham and Women's Hospital, Boston, led the new stent analysis. ...

CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity

... be used to control bleeding episodes in hemophilia patients with inhibitors. These patients develop an immune response that inhibits the substituted clotting factor from stopping a bleeding episode. However, rFVIIa has a short half-life of approximately 2.5 hours. This necessitates multiple injections, ...

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

... with LOVENOX(R). LOVENOX(R) can alter the blood's ability to clot. Patients treated with LOVENOX(R), who also have conditions affecting the clotting system, must be carefully monitored by their physician. Adjusting the dose of LOVENOX(R) may be necessary for patients who have certain forms of ...

Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood

... to sickle cell disease and thalassemia, press briefings will take place at the annual meeting focusing on leukemias, hematologic malignancies, blood clotting and bleeding disorders, and transplantation. The study authors and press program moderator will be available for interviews after the press program ...

Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B

... to people worldwide." About Hemophilia Hemophilia is a lifelong, inherited bleeding disorder caused by low levels, or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in ...

Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium

... sodium did not change the antiplatelet effect profile seen with aspirin therapy alone. The aggregation or accumulation of platelets can cause clotting in the arteries, which can lead to a heart attack or ischemic stroke. It has been reported that one in five Americans (an estimated 43 million) ...

Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions

... In Phase I Clinical Evaluation Anticoagulant Inhibits clotting Factor IXa; Matched Antidote Rapidly Reverses Anticoagulant Effect ORLANDO, Fla., Nov. 6 /PRNewswire/ -- Regado Biosciences today presented ...